DrugDashboards

Remifentanil Hydrochloride

Remifentanil Hydrochloride · REMIFENTANIL HYDROCHLORIDE 1 mg/mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Fresenius Kabi USA, LLC

NDC 63323-0725-10 · 10 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “demand increase for the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Federal contracts pay (FSS)$2,664.30per package of 10 x 10MLFresenius Kabi, LLC · May 15, 2025
  • List price (WAC, as filed)$3,399.60per packageFresenius Kabi USA · Feb 19, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$3,399.60
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA206223
TE code
AP
Approval date
Jan 16, 2018
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)Jun 28, 2022
    Demand increase for the drug
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)Jun 28, 2022
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)Jun 28, 2022
    Delay in shipping of the drug
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)Jun 28, 2022
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)Jun 28, 2022
    Demand increase for the drug
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)Jun 28, 2022
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)Jun 28, 2022
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Ultiva, Injection, 2 mg (NDC 72078-035-02)Jun 28, 2022
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Ultiva, Injection, 5 mg (NDC 72078-036-05)Jun 28, 2022
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Remifentanil Hydrochloride (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCREMIFENTANIL HYDROCHLORIDE 1 mg/mLJul 15, 2026Sep 3, 2026
Mylan Institutional LLCREMIFENTANIL HYDROCHLORIDE 1 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.REMIFENTANIL HYDROCHLORIDE 1 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.REMIFENTANIL HYDROCHLORIDE 2 mg/2mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.REMIFENTANIL HYDROCHLORIDE 5 mg/5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Remifentanil Hydrochloride — NDC 63323-0725-10," retrieved September 3, 2026, https://drugdashboards.com/drug/63323072510.

Free to cite with attribution — see how the data is put together.